Biography for Maureen Martino
Maureen Martino is the managing editor of the FierceMarkets Life Sciences group and a contributor to FierceBiotech and FierceMedicalDevices. She is a graduate of Franklin & Marshall College in Lancaster, PA. Prior to joining FierceMarkets in 2005, she was an intern at Johnson & Johnson's business development unit and quality control and compliance group. Maureen is passionate about covering emerging live science companies, breakthrough technologies and biopharma M&A. She loves traveling, reading, cooking and is a classically-trained pianist. Maureen is based in the Philadelphia area, and can be reached at email@example.com. You can follow her at @FierceBiotech on Twitter and find her on LinkedIn.
Articles by Maureen Martino
The FDA has proposed new guidelines for the de novo clearance process that the agency says could shave 90 days off approval period of some devices. Currently, only devices that have already been
UC Davis researchers have turned an iPhone into a medical device capable of performing detailed microscopy. By attaching an inexpensive ball lens to the iPhone's existing camera, the scientists
Maquet Cardiovascular, a subsidiary of Sweden's Getinge Group, is paying $680 million to acquire U.S.-based medical device company Atrium Medical. The move marks Getinge's largest acquisition in four
Boston Scientific will cut up to 1,400 jobs by the end of 2013 to save $275 million, the company revealed in its second quarter earnings report. The cuts will be achieved through a combination of
Johnson & Johnson Development Corporation led a $58 million financing for Nervo Corp., a pain management company that's developing a new spinal cord stimulation (SCS) therapy intended to provide
King's College London has spun out Centron Diagnostics, a start-up that will use new technology to measure central blood pressure. The device, which is worn on the arm, will measure both traditional
Reductions in stock options and bonuses caused Boston Scientific CEO Ray Elliott's pay to plummet 86 percent in 2010 to $4.7 million. The CEO earned $33.4 million the previous year. Elliott, the
Atlanta-based CryoLife has inked a deal to buy Cardiogenesis Corporation for $22 million--a 43 percent premium to Cardiogenesis' closing price on March 28. The Irvine, CA-based developer makes
GI Dynamics has a fresh set of positive clinical results from three studies of its EndoBarrier Gastrointestinal Liner, a device used to treat type 2 diabetes, weight loss and other metabolic factors.
A device developed by retired U.S. Navy sonar experts could allow physicians to better diagnose and monitor potential stroke victims. At the Society of Interventional Radiology's 36th Annual